Consensus Report on the Future of Animal-Free Systemic Toxicity Testing
Owner/Developer: Alternatives to Animal Experimentation (ALTEX)
Country: | Switzerland |
---|---|
Languages: | English |
Url: | http://www.altex.ch/resources/altex_2014_3_341_356_4f_T4Leist1.pdf |
Description: |
Since March 2013, animal use for cosmetics testing for the European market has been banned. This requires a renewed view on risk assessment in this field. However, in other fields as well, traditional animal experimentation does not always satisfy requirements in safety testing, as the need for human-relevant information is ever increasing. A general strategy for animal-free test approaches was outlined by the US National Research Council’s vision document for Toxicity Testing in the 21st Century in 2007. It is now possible to provide a more defined roadmap on how to implement this vision for the four principal areas of systemic toxicity evaluation: repeat dose organ toxicity, carcinogenicity, reproductive toxicity and allergy induction (skin sensitization), as well as for the evaluation of toxicant metabolism (toxicokinetics). [...] Finally, quantitative information on all factors and key events will be fed into systems biology models that allow a probabilistic risk assessment with flexible adaptation to exposure scenarios and individual risk factors. |
Category: | Publication |
Channel: | Website - Printed |
Audience: | Scientists - Policy-makers - Regulators - Industry - Researchers - Students |
User access: | Open access |
Updating frequency: | 2014 |
Relevance: | Replacement |
Purpose: | Toxicological and safety evaluation - Documentation and information - Validation |
Did you find what you were looking for?
Yes, I found it! No, I did not!Thanks for your feedback! Please note that we cannot reply to you unless you send us an email.
What are you looking for?
We value your feedback so we can improve the information on the page. Please add your email address if you would like a reply. Thank you in advance for your help.!
Please contact us by email if you have any questions.